Second breast conserving therapy after ipsilateral breast tumor recurrence - a 10-year experience of re-irradiation.
brachytherapy
breast cancer
ipsilateral breast tumor recurrence
re-irradiation
second breast conserving therapy
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
10
04
2019
accepted:
31
05
2019
entrez:
17
9
2019
pubmed:
17
9
2019
medline:
17
9
2019
Statut:
ppublish
Résumé
The aim of this study is to evaluate the efficacy and toxicity of post-operative partial breast re-irradiation with multi-catheter brachytherapy after second breast conserving therapy (BCT) in patients with small, low-risk ipsilateral breast tumor recurrence (IBTR). Between 2008 and 2018, 19 consecutive patients with low-risk IBTR (max. rpT1 cN0 cM0, Her2 negative, preferably positive hormone receptor status) who refused mastectomy were treated with salvage lumpectomy, followed by post-operative partial breast re-irradiation with multi-catheter brachytherapy. Eight patients were irradiated using PDR brachytherapy (49.8-50.4 Gy in pulses of 0.5-0.7 Gy) and 11 patients using HDR brachytherapy (34.2 Gy in fractions of 3.8 Gy or 32 Gy in fractions of 4 Gy). All patients had undergone prior BCT for their primary tumor, followed by adjuvant whole breast radiotherapy. Local control (LC), locoregional control (LRC), overall survival (OS), disease-free survival (DFS) as well as toxicity were evaluated in the present study. After a median follow-up of 65 months following IBTR (18-120 months), only one second IBTR in 19 patients was diagnosed 77 months after re-irradiation, resulting in a LC rate of 100% at 5 years. DFS and OS rates were both 100% at 5 years following re-irradiation. Except for the above mentioned second IBTR, no regional or distant relapse was recorded. Regarding toxicity, 63% of patients developed adverse events (CTCAE grade ≤ 2), with fibrosis detected in 37% (7/19) of patients, necrosis in 11% (2/19), hyperpigmentation in 47% (9/19), and telangiectasia in 11% (2/19), respectively. No patient showed a high-grade (CTCAE grade ≥ 3) adverse event. In case of small, low-risk IBTR, adjuvant re-irradiation using multi-catheter brachytherapy is a feasible, safe, and effective treatment method after repeated lumpectomy, and an alternative to mastectomy.
Identifiants
pubmed: 31523231
doi: 10.5114/jcb.2019.87001
pii: 37355
pmc: PMC6737570
doi:
Types de publication
Journal Article
Langues
eng
Pagination
312-319Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Breast Cancer Res Treat. 1999 Mar;54(1):47-57
pubmed: 10369080
J Natl Cancer Inst. 2000 Sep 6;92(17):1422-9
pubmed: 10974078
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):687-91
pubmed: 12062613
J Clin Oncol. 2002 Oct 1;20(19):4050-64
pubmed: 12351603
Radiology. 2002 Dec;225(3):713-8
pubmed: 12461250
Breast J. 2004 May-Jun;10(3):223-31
pubmed: 15125749
Cancer. 1992 Apr 1;69(7):1729-38
pubmed: 1551058
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1385-92
pubmed: 15590169
Breast Cancer. 2005;12(2):104-11
pubmed: 15858440
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):845-51
pubmed: 16199315
Strahlenther Onkol. 2006 Feb;182(2):102-7
pubmed: 16447017
BMC Cancer. 2007 Sep 14;7:178
pubmed: 17854511
Br J Cancer. 2007 Dec 17;97(12):1625-31
pubmed: 18000503
Eur J Cancer. 1991;27(3):240-4
pubmed: 1827303
Brachytherapy. 2008 Jan-Mar;7(1):22-8
pubmed: 18299110
J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83
pubmed: 18695137
J Clin Oncol. 2009 May 20;27(15):2466-73
pubmed: 19349544
J Am Coll Surg. 2009 Aug;209(2):269-77
pubmed: 19632605
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):804-10
pubmed: 20106605
Lancet. 2010 Jul 10;376(9735):91-102
pubmed: 20570343
Brachytherapy. 2011 May-Jun;10(3):171-7
pubmed: 20685178
Radiother Oncol. 2012 Jan;102(1):96-101
pubmed: 21907439
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Oncology. 2011;81(5-6):381-6
pubmed: 22269927
Radiother Oncol. 2012 May;103(2):161-5
pubmed: 22280804
Magy Onkol. 2012 May;56(2):68-74
pubmed: 22629542
Cancer Treat Rev. 2013 Nov;39(7):737-41
pubmed: 23465859
Radiother Oncol. 2013 Aug;108(2):226-31
pubmed: 23647758
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Lancet Oncol. 2015 Mar;16(3):266-73
pubmed: 25637340
Ann Agric Environ Med. 2015;22(1):185-9
pubmed: 25780852
Tumour Biol. 2016 Jun;37(6):7675-84
pubmed: 26687919
Radiother Oncol. 2016 Jan;118(1):199-204
pubmed: 26776444
Strahlenther Onkol. 2016 Apr;192(4):199-208
pubmed: 26931319
J BUON. 2016 Nov-Dec;21(6):1425-1432
pubmed: 28039703
Breast Cancer Res Treat. 2017 Jun;163(3):517-526
pubmed: 28324266
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1028-1035
pubmed: 28721885
J Contemp Brachytherapy. 2018 Feb;10(1):58-63
pubmed: 29619057
Radiother Oncol. 2018 Sep;128(3):411-420
pubmed: 29691075
J Contemp Brachytherapy. 2018 Apr;10(2):97-104
pubmed: 29789758
Strahlenther Onkol. 2018 Sep;194(9):806-814
pubmed: 29796694
J Plast Reconstr Aesthet Surg. 2019 Mar;72(3):394-400
pubmed: 30509735
Breast Cancer Res Treat. 2019 Jul;176(1):149-157
pubmed: 30949798
Cancer. 1988 May 15;61(10):1969-72
pubmed: 3129175
N Engl J Med. 1981 Jul 2;305(1):6-11
pubmed: 7015141
J Clin Oncol. 1993 Jan;11(1):44-8
pubmed: 8418240
J Clin Oncol. 1996 Oct;14(10):2747-55
pubmed: 8874336
Cancer. 1998 Nov 15;83(10):2130-8
pubmed: 9827717